![[SEBASTIAN KAULITZKI] - STOCK.ADOBE.COM](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/3fbe7b21eef28f23798900792090beea0407b955-950x1030.png?w=350&fit=crop&auto=format)
Determining treatment options for patients with locally advanced rectal cancer after the PROSPECT trial data readout adds an important level to the decision-making process.
Manju George, PhD
Advertisement
Articles by Manju George, PhD
Advertisement
Latest Updated Articles
![[SEBASTIAN KAULITZKI] - STOCK.ADOBE.COM](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/3fbe7b21eef28f23798900792090beea0407b955-950x1030.png?w=300&fit=crop&auto=format)
Advertisement
Advertisement
Trending on CancerNetwork
1
Prior Regimen Did Not Affect Daraxonrasib Benefit in Pretreated Pancreatic Cancer
2
Petosemtamab/Pembrolizumab Improves OS in First-Line PD-L1–Positive HNSCC
3
What Are the Top Takeaways for Neuroendocrine Carcinoma From 2026 ESMO?
4
Sacituzumab Govitecan PFS Benefit Holds Across Subgroups in Untreated mTNBC
5